Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06219720 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Texas Interprofessional Pharmacogenomics (IPGx)

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv2
  2. Study First Submitted
The investigator's primary aim is to evaluate polypharmacy-associated adverse drug reactions (ADR) in a pilot study of at-risk patients using state-of-the-art pharmacogenomic technology and to use this information to make recommendations for optimization of pharmacotherapy regimens. The data from the pilot cohort will be used to optimize and integrate a customized electronic decision support (clinical semantic network; CSN) dashboard to identify drug regimens that should be modified, replaced, or discontinued. A secondary objective of the pilot study is to evaluate the capacity/saturation of CYP P450 enzymatic pathways in polypharmacy patients. A third objective is to determine the feasibility of the planned informatics workflows between the CLIA lab, the EMR, and the Family Medicine Practice.
Trial Details
NCT Number NCT06219720
Lead Sponsor Texas A&M University
Collaborators: InnovativeGx, Texas A&M Health Family Care Clinic, iC42 Clinical Research and Development, Goldblatt systems
Conditions
(from sponsor)		 Adverse Drug Reaction
Related terms Drug-Related Side Effects and Adverse Reactions
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov